Critical appraisal of cabazitaxel in the management of advanced prostate cancer.

Clinical interventions in aging

Volumn 5, Issue , 2010, Pages 395-402

  Pal, Sumanta Kumar ^a   Twardowski, Przemyslaw ^b   Sartor, Oliver ^b  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETOXY 13 ((3 ((TERT BUTOXYCARBONYL)AMINO) 2 HYDROXY 3 PHENYLPROPANOYL)OXY) 1 HYDROXY 7,10 DIMETHOXY 9 OXO 5,20 EPOXYTAX 11 EN 2 YL BENZOATE; 4-ACETOXY-13-((3-((TERT-BUTOXYCARBONYL)AMINO)-2-HYDROXY-3-PHENYLPROPANOYL)OXY)-1-HYDROXY-7,10-DIMETHOXY-9-OXO-5,20-EPOXYTAX-11-EN-2-YL BENZOATE; ANTINEOPLASTIC AGENT; DOCETAXEL; PREDNISONE; TAXOID;

ANIMAL; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DRUG RESISTANCE; FEMALE; HUMAN; MALE; MOUSE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE TUMOR; RAT; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MICE; NEUTROPENIA; PREDNISONE; PROSTATIC NEOPLASMS; RATS; TAXOIDS;

MLCS; MLOWN;

EID: 79952638007     PISSN: None     EISSN: 11781998     Source Type: Journal    
DOI: 10.2147/cia.s14570     Document Type: Review

References (0)